fda glp-1 warning 2025 november letters FDA issued 30 warning letters to telehealth companies for GLP-1 Pipeline Update: August 2025
Description
WHO GLP-1 Treatments: The World Health Organization has issued new guidelines endorsing GLP-1 agonists as essential treatments for obesity, highlighting the urgent need for action against the rising global obesity epidemic affecting over one billion people and posing serious health risks.
The GLP-1 market is led by semaglutide products Ozempic and Wegovy (Novo Nordisk) and tirzepatide products Mounjaro and Zepbound (Lilly)
FDA issued 30 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products
Patients are suing Novo Nordisk over gastroparesis, intestinal blockages and permanent vision loss (NAION) linked to Ozempic
Learn how GLP-1 dose increases work for semaglutide and tirzepatide
